RKDA Insider Trading Activity and SEC Form 4 Filings
RKDA insider trading summary
No open-market insider purchases or sales of Arcadia Biosciences, Inc. (RKDA) have been reported on SEC Form 4 in the past 12 months.
Latest RKDA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 3, 2025 | Mark Kawakami | Chief Financial Officer | Buy | $2K (700 @ $2.49) |
| Feb 3, 2025 | Thomas J. Schaefer | Chief Executive Officer | Buy | $2K (700 @ $2.49) |
| Aug 1, 2024 | Mark Kawakami | Chief Financial Officer | Buy | $1K (700 @ $2.06) |
| Aug 1, 2024 | Thomas J. Schaefer | Chief Executive Officer | Buy | $1K (700 @ $2.06) |
| Feb 1, 2024 | Thomas J. Schaefer | Chief Financial Officer | Buy | $1K (700 @ $2.06) |
| Aug 4, 2023 | Thomas J. Schaefer | Chief Financial Officer | Buy | $2K (649 @ $3.67) |
| May 30, 2023 | Stanley Jacot Jr | Chief Executive Officer | Buy | $22K (5,000 @ $4.31) |
| Feb 1, 2023 | Thomas J. Schaefer | Chief Financial Officer | Buy | $161 (700 @ $0.23) |
| Aug 1, 2022 | Pamela Haley | Chief Financial Officer | Buy | $490 (700 @ $0.70) |
| Aug 3, 2020 | Matthew T Plavan | Chief Executive Officer | Buy | $2K (585 @ $3.16) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.